Display options
Cite
Glassman A, Shapiro PA, Ford DE, et al. Cardiovascular health and depression. J Psychiatr Pract. 2003;9(6):409-21doi: 10.1097/00131746-200311000-00004.
Glassman, A., Shapiro, P. A., Ford, D. E., Culpepper, L., Finkel, M. S., Swenson, J. R., Bigger, J. T., Rollman, B. L., & Wise, T. N. (2003). Cardiovascular health and depression. Journal of psychiatric practice, 9(6), 409-21. https://doi.org/10.1097/00131746-200311000-00004
Glassman, Alexander, et al. "Cardiovascular health and depression." Journal of psychiatric practice vol. 9,6 (2003): 409-21. doi: https://doi.org/10.1097/00131746-200311000-00004
Glassman A, Shapiro PA, Ford DE, Culpepper L, Finkel MS, Swenson JR, Bigger JT, Rollman BL, Wise TN. Cardiovascular health and depression. J Psychiatr Pract. 2003 Nov;9(6):409-21. doi: 10.1097/00131746-200311000-00004. PMID: 15985964.
Copy Download .nbib Format: NLM
Share it on

J Psychiatr Pract. 2003 Nov;9(6):409-21. doi: 10.1097/00131746-200311000-00004.

Cardiovascular health and depression.

Journal of psychiatric practice

Alexander Glassman, Peter A Shapiro, Daniel E Ford, Larry Culpepper, Mitchell S Finkel, J Robert Swenson, J Thomas Bigger, Bruce L Rollman, Thomas N Wise

Affiliations

  1. Columbia University, New York, NY 10032, USA.

PMID: 15985964 DOI: 10.1097/00131746-200311000-00004

Abstract

Research has shown that depression increases the likelihood that otherwise healthy people will develop ischemic heart disease (IHD) and worsens the prognosis of patients who already have IHD. Moreover, concerns about safety (e.g., cardiac side effects, drug-drug interactions) have caused physicians to be hesitant about using antidepressant agents in patients with IHD. This article is based on a recent roundtable of experts who met to discuss risk, diagnosis, and treatment options for depression in patients with IHD. This article reviews clinical and epidemiological studies that have described a link between depression and the subsequent development of IHD and have examined the role of depression as a predictor of cardiac events in patients with existing IHD. The article addresses the issue of whether depression can be safely and efficaciously treated both in patients with stable IHD and in those with acute coronary syndromes. The authors discuss safety issues related to the potential for interactions between antidepressants and cardiovascular medications, the use of nonpharmacologic treatment options such as psychosocial interventions, and the effect of antidepressant therapy on quality of life in patients with IHD. The article concludes with practical clinical guidance concerning the management of depression in patients who have recently experienced myocardial infarction.

Publication Types